相关实验视频
Updated: May 7, 2025

07:44
A Porcine Model of Acute Autologous Pulmonary Embolism
Published on: September 6, 2024
246
肺栓塞患者住院患者初始抗凝选择的因素
William B Stubblefield1, Ron Helderman2, Natalie Strokes3
1Department of Emergency Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
JAMA network open
|January 3, 2025
概括
医生经常在急性肺栓塞 (PE) 时使用未分离的肝素 (UFH),尽管指南建议使用其他抗凝剂. 关键的障碍包括根深蒂固的做法,机构文化和对治疗的误解.
科学领域:
- 肺部医学 肺部医学
- 药理学 药理学是指药理学的学科.
- 定性研究是指质量研究.
背景情况:
- 指南建议低分子量肝素 (LMWH) 或直接口服抗凝剂用于急性肺栓塞 (PE).
- 美国的研究表明,与建议相反,在住院PE患者中越来越多地使用未分离的肝素 (UFH).
研究的目的:
- 在住院急性PE患者中确定与指导方针一致的抗凝剂的障碍物和促进因素.
- 了解医生关于选择PE抗凝剂的决策.
主要方法:
- 使用半结构面试与急诊医学,医院医学,干预心脏病学和干预放射学医生的定性研究.
- 对录制和转录的采访进行反思性的专题分析.
- 最大变异采样以捕捉不同的抗凝剂方法;结果与干预专家三角化.
主要成果:
- 医生的主题包括关于抗凝药选择的"不可知论"",学会实践的惯性"和"治疗势头".
- 机构文化和支持影响了主流的抗凝血策略.
- 有利于UFH的因素包括对失补偿的恐惧和对抗凝血剂和导管治疗药理学的误解.
结论:
- 医生报告了针对急性PE的指导方针一致的抗凝药的常见障碍.
- 这些包括选择的"不可知论",根深蒂固的做法,治疗势头和制度因素.
- 未来的实施工作应解决这些已识别的领域,以改善准则的遵守.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
528
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
528
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
981
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
981
Disorders of Hemostasis
633
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
633
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
97
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
97
Clot Retraction and Fibrinolysis
2.3K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
2.3K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
89
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
89

